Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Teniposide plus cisplatin or carboplatin in recurrent high-grade glioma
ChiCTR2300073961Phase 4Not yet recruiting
- Sponsor
- Beijing Tiantan Hospital
- Start
- Jul 2023
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of teniposide, cisplatin and carboplatin in glioma, sponsored by Beijing Tiantan Hospital. Primary endpoints: Tumor evaluation (RANO-based) and Overall survival. Planned start Jul 2023; status: not yet recruiting.
02
Drugs
teniposidecisplatincarboplatin
03
Conditions
glioma
Beyond the preview
Go deeper on ChiCTR2300073961.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300073961.